Language:

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

The New England journal of medicine, 2013-10, Vol.369 (14), p.1317-1326 [Peer Reviewed Journal]

Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1307684 ;PMID: 23992601 ;CODEN: NEJMAG

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Author: Scirica, Benjamin M ; Bhatt, Deepak L ; Braunwald, Eugene ; Steg, P. Gabriel ; Davidson, Jaime ; Hirshberg, Boaz ; Ohman, Peter ; Frederich, Robert ; Wiviott, Stephen D ; Hoffman, Elaine B ; Cavender, Matthew A ; Udell, Jacob A ; Desai, Nihar R ; Mosenzon, Ofri ; McGuire, Darren K ; Ray, Kausik K ; Leiter, Lawrence A ; Raz, Itamar
Subjects: Adamantane - adverse effects ; Adamantane - analogs & derivatives ; Adamantane - therapeutic use ; Aged ; Aged, 80 and over ; Angina ; Biological and medical sciences ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - mortality ; Cerebral infarction ; Complications and side effects ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Dipeptides - adverse effects ; Dipeptides - therapeutic use ; Dipeptidyl-peptidase IV ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Dosage and administration ; Double-Blind Method ; Drug therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; General aspects ; Heart attacks ; Heart diseases ; Heart Failure - epidemiology ; Heart rate ; Hospitalization - statistics & numerical data ; Humans ; Hypoglycemia - chemically induced ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Ischemia ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Medicin och hälsovetenskap ; Middle Aged ; Myocardial infarction ; Pancreatitis ; Pancreatitis - chemically induced ; Pancreatitis - epidemiology ; Patient outcomes ; Patients ; Peptidase ; Risk factors ; Saxagliptin ; Type 2 diabetes
Is Part Of: The New England journal of medicine, 2013-10, Vol.369 (14), p.1317-1326
Description: Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2 diabetes. Although the drug does not increase cardiovascular risk, it also does not provide cardiovascular benefit. Type 2 diabetes mellitus doubles the risk of major cardiovascular complications in patients with and in patients without established cardiovascular disease, 1 – 3 such that the majority of patients with diabetes die of cardiovascular diseases. 4 Although improved glycemic control has repeatedly been shown to reduce microvascular diabetic complications, 5 uncertainty remains regarding whether any particular glucose-lowering strategy, or specific therapeutic agent, is safe from a cardiovascular standpoint or can actually lower cardiovascular risk. With the possible exception of trials of metformin 6 and insulin, 7 most reported trials to date evaluating the effects on cardiovascular outcomes of specific glucose-lowering strategies or medications either have . . .
Publisher: Waltham, MA: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
ISSN: 1533-4406
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1307684
PMID: 23992601
CODEN: NEJMAG
Source: ProQuest One Psychology
MEDLINE
Alma/SFX Local Collection
SWEPUB Freely available online
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1307684 ;PMID: 23992601 ;CODEN: NEJMAG

Searching Remote Databases, Please Wait